Cansino Historical Income Statement

688185 Stock

61.23 0.13 0.21%

Historical analysis of Cansino Biologics income statement accounts such as Interest Income of 105.1 M, Interest Expense of 67.4 M or Selling General Administrative of 680.2 M can show how well Cansino Biologics performed in making a profits. Evaluating Cansino Biologics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cansino Biologics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cansino Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cansino Biologics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Cansino Income Statement Analysis

Cansino Biologics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cansino Biologics shareholders. The income statement also shows Cansino investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cansino Biologics Income Statement Chart

At present, Cansino Biologics' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 67.4 M, whereas Tax Provision is forecasted to decline to (12 M).

Tax Provision Interest Income Interest Expense Operating Income Cost Of Revenue Total Operating Expenses

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Operating Income

Operating Income is the amount of profit realized from Cansino Biologics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cansino Biologics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Cansino Biologics income statement and represents the costs associated with goods and services Cansino Biologics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Cansino Biologics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cansino Biologics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Interest Income	79.7M	65.9M	100.1M	105.1M
Net Interest Income	59.0M	24.1M	35.7M	27.1M

Interest Income Net Interest Income

Cansino Biologics income statement Correlations

	Net Interest Income	Interest Income	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Net Income	Income Tax Expense
Net Interest Income		0.84	0.7	0.5	0.92	-0.03	0.03	0.08	0.91	0.24	0.77	0.83	0.61	0.02	0.13	-0.43
Interest Income	0.84		0.97	0.08	0.89	-0.48	-0.42	-0.34	0.88	-0.19	0.85	0.89	0.94	-0.43	-0.32	-0.81
Selling General Administrative	0.7	0.97		-0.1	0.84	-0.63	-0.57	-0.52	0.83	-0.37	0.85	0.88	0.99	-0.59	-0.48	-0.93
Gross Profit	0.5	0.08	-0.1		0.34	0.83	0.87	0.86	0.38	0.94	0.31	0.29	-0.23	0.86	0.91	0.38
Other Operating Expenses	0.92	0.89	0.84	0.34		-0.22	-0.14	-0.13	0.97	0.05	0.94	0.98	0.76	-0.16	-0.05	-0.67
Operating Income	-0.03	-0.48	-0.63	0.83	-0.22		0.99	0.97	-0.19	0.95	-0.24	-0.28	-0.72	1.0	0.98	0.82
Net Income From Continuing Ops	0.03	-0.42	-0.57	0.87	-0.14	0.99		0.96	-0.1	0.95	-0.15	-0.19	-0.68	1.0	0.99	0.76
Ebit	0.08	-0.34	-0.52	0.86	-0.13	0.97	0.96		-0.12	0.98	-0.14	-0.19	-0.6	0.97	0.98	0.76
Research Development	0.91	0.88	0.83	0.38	0.97	-0.19	-0.1	-0.12		0.07	0.93	0.97	0.74	-0.13	-0.02	-0.66
Ebitda	0.24	-0.19	-0.37	0.94	0.05	0.95	0.95	0.98	0.07		0.04	-0.01	-0.47	0.96	0.99	0.63
Cost Of Revenue	0.77	0.85	0.85	0.31	0.94	-0.24	-0.15	-0.14	0.93	0.04		0.99	0.79	-0.18	-0.06	-0.73
Total Operating Expenses	0.83	0.89	0.88	0.29	0.98	-0.28	-0.19	-0.19	0.97	-0.01	0.99		0.81	-0.22	-0.1	-0.75
Reconciled Depreciation	0.61	0.94	0.99	-0.23	0.76	-0.72	-0.68	-0.6	0.74	-0.47	0.79	0.81		-0.69	-0.59	-0.95
Income Before Tax	0.02	-0.43	-0.59	0.86	-0.16	1.0	1.0	0.97	-0.13	0.96	-0.18	-0.22	-0.69		0.99	0.78
Net Income	0.13	-0.32	-0.48	0.91	-0.05	0.98	0.99	0.98	-0.02	0.99	-0.06	-0.1	-0.59	0.99		0.7
Income Tax Expense	-0.43	-0.81	-0.93	0.38	-0.67	0.82	0.76	0.76	-0.66	0.63	-0.73	-0.75	-0.95	0.78	0.7

Click cells to compare fundamentals

Cansino Biologics Account Relationship Matchups

Cansino Biologics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	21.8M	31.6M	59.0M	24.1M	35.7M	27.1M
Interest Income	21.8M	31.7M	79.7M	65.9M	100.1M	105.1M
Interest Expense	11.9M	26.5M	20.4M	41.3M	64.1M	67.4M
Selling General Administrative	68.1M	99.4M	337.6M	544.7M	647.8M	680.2M
Total Revenue	5.7M	18.5M	4.3B	1.0B	345.2M	327.9M
Gross Profit	2.1M	4.7M	3.0B	(186.6M)	(876.0M)	(832.2M)
Other Operating Expenses	3.0M	3.9M	10.2M	8.4M	9.6M	4.8M
Operating Income	(204.2M)	(440.3M)	1.8B	(1.4B)	(2.1B)	(2.0B)
Net Income From Continuing Ops	(156.8M)	(396.6M)	1.9B	(964.8M)	(2.0B)	(1.9B)
Ebit	(217.9M)	(517.7M)	1.8B	(1.5B)	(1.4B)	(1.3B)
Research Development	151.7M	428.5M	878.7M	778.3M	638.0M	480.4M
Ebitda	(134.3M)	(364.8M)	2.0B	(946.3M)	(1.1B)	(1.0B)
Cost Of Revenue	147.5K	13.8M	1.3B	1.2B	1.2B	617.7M
Total Operating Expenses	204.2M	458.9M	2.5B	2.5B	2.4B	1.3B
Reconciled Depreciation	22.5M	31.8M	88.5M	196.4M	269.1M	282.5M
Income Before Tax	(156.8M)	(396.6M)	1.9B	(1.2B)	(2.0B)	(1.9B)
Net Income Applicable To Common Shares	(156.8M)	(396.6M)	1.9B	(909.4M)	(1.0B)	(993.6M)
Net Income	(156.8M)	(396.6M)	1.9B	(909.4M)	(1.5B)	(1.4B)

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

Other Information on Investing in Cansino Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cansino Historical Income Statement

About Cansino Income Statement Analysis

Cansino Biologics Income Statement Chart

Tax Provision

Interest Income

Interest Expense

Operating Income

Cost Of Revenue

Total Operating Expenses

Cansino Biologics income statement Correlations

Cansino Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cansino Biologics income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Reconciled Depreciation	+ 0.99	Selling General Administrative
Net Income From Continuing Ops	+ 0.99	Operating Income
Net Income	+ 0.99	Net Income From Continuing Ops
Net Income	+ 0.99	Ebitda

Income Tax Expense	- 0.95	Reconciled Depreciation
Income Tax Expense	- 0.93	Selling General Administrative
Income Tax Expense	- 0.81	Interest Income
Income Tax Expense	- 0.75	Total Operating Expenses
Income Tax Expense	- 0.73	Cost Of Revenue
Reconciled Depreciation	- 0.72	Operating Income